MHLW Approves Sandoz's Somatropin As First Biosimilar Product In Japan
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Japan's Ministry of Health, Labor and Welfare has approved Sandoz's recombinant human growth hormone somatropin injection, marking it the first biosimilar product approved in Japan, a MHLW Pharmaceutical Examination Division official confirmed June 26